Metastatic Castrate Resistant Prostate Cancer (mCRPC) research hub
3 indexed studies · 1 currently recruiting
- active not recruitingPHASE4
RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)
This study compares two treatments, Radium-223 (Xofigo) and ARPI therapy, for prostate cancer that has spread to the bones. It aims to see which is more effective and safer for men who have already tried ARPIs.
Australia · Austria · Czechia - recruitingPHASE1, PHASE2
Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer
This study is looking into a new combination of medicines, SX-682 and Apalutamide, for men with prostate cancer that has spread and is no longer responding to standard hormone therapy. We want to see if this new combination can help slow down the cancer.
Switzerland · United Kingdom - active not recruitingPHASE3
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
This study looks at a new medicine, PF-06821497, combined with enzalutamide for men with advanced prostate cancer that has spread. It compares this combination to standard treatments like enzalutamide or docetaxel to see if it's safer and works better after previous abiraterone treatment.
United States · Argentina · Australia